SCHEMBL642325

SCHEMBL642325

COc1ccc(S(=O)(=O)n2c(=O)n(C(Cc3ccccc3)C(=O)N3CCN(c4ccncc4)CC3)c3cc(Cl)ccc32)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MAPK1 P28482 2/20 0.49
TP53 P04637 1/20 0.49
ALOX15 P16050 1/20 0.49
HSD17B10 Q99714 1/20 0.49
HTT P42858 4/20 0.42
GAA P10253 2/20 0.42
LMNA P02545 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
F10 P00742 2/20 0.41
P2RX7 Q99572 4/20 0.39
ALDH1A1 P00352 3/20 0.39
PKM P14618 1/20 0.39
GFER P55789 2/20 0.39
TSHR P16473 1/20 0.39
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL639678 0.91 MAPT (0.46) MAPTSMN1; SMN2MAPK1TP53ALOX15
SCHEMBL640140 0.89 HTT (0.42) MAPTSMN1; SMN2MAPK1TP53ALOX15
SCHEMBL641231 0.88 MAPK1 (0.42) MAPTSMN1; SMN2MAPK1HTTGAA
SCHEMBL642439 0.86 MAPT (0.43) MAPTSMN1; SMN2MAPK1HTTGAA
SCHEMBL640444 0.85 F10 (0.42) MAPTSMN1; SMN2MAPK1HTTGAA
SCHEMBL640845 0.85 AVPR1B (0.42) MAPTSMN1; SMN2ALOX15HTTGAA
SCHEMBL640089 0.85 MAPK1 (0.42) MAPTSMN1; SMN2MAPK1GAALMNA
SCHEMBL641245 0.83 ROCK2 (0.47) MAPTMAPK1GAALMNANPSR1
SCHEMBL641164 0.82 ALDH1A1 (0.46) MAPTSMN1; SMN2MAPK1TP53ALOX15
SCHEMBL639916 0.80 AVPR1B (0.41) MAPTSMN1; SMN2MAPK1HTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791148-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use AbbVie Deutschland GmbH & Co. KG (DE) 2014-07-29 US disclosed
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2012-07-05 US disclosed
US-8119676-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use Abbott GmbH & Co. HG (DE) 2012-02-21 US disclosed
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2010-06-17 US disclosed
EP-2061769-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE Abbott GmbH & Co. KG (DE) 2009-05-27 EP disclosed
WO-2008025736-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A MAPT 4368/4885SMN1; SMN2 3474/4885MAPK1 2454/4885
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A MAPT 4368/4885SMN1; SMN2 3474/4885MAPK1 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.